26 unknown, 22 recruiting, 17 completed, 7 active not recruiting. 26 Phase 2, 17 Phase 4, 15 Not applicable, 14 Phase 1, 10 Phase 3.
Follow pegylated granulocyte colony-stimulating factor: new trials by email Literature Review of pegylated granulocyte colony-stimulating factor trials Research Report on pegylated granulocyte colony-stimulating factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| PEG-rhG-CSF Primary Prophylaxis vs Therapeutic Short-Acting rhG-CSF for Neutropenia During Pelvic Chemoradiotherapy in Cervical or Endometrial Cancer Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor (PEG-rhG-CSF), Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) - Cervical Cancer, Endometrial Cancer | Not applicable | Active not recruiting | The Second Hospital of Anhui Medical University | 90 | 2026-09-15 | 2026-10-08 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-05-08 | 2026-07-28 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection Mecapegfilgrastim Injection - Neutropenia | Recruiting | Hebei Medical University Fourth Hospital | 200 | 2025-06-18 | 2026-02-25 | |
| Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors Telpegfilgrastim Injection, filgrastim - Solid Tumors, Children | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 132 | 2025-06-12 | 2026-05-07 |
| Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas PEEL-224, Temozolomide, Vincristine - Sarcoma, Sarcoma, Ewing | Phase 1 / Phase 2 | Recruiting | David S Shulman, MD | 63 | 2025-01-27 | 2026-02-19 |
| Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC Mecapegfilgrastim, Adebrelimab, Docetaxel - GC/GEJC | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 70 | 2024-11-30 | 2024-11-12 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients Etoposide, Cytarabine, Pegfilgrastim - Multiple Myeloma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2024-07-25 |
| A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies HHPG-19K Injection - Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk | Phase 3 | Withdrawn | Jiangsu HengRui Medicine Co., Ltd. | 2024-02-01 | 2025-08-07 | |
| The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization PEG-rhG-CSF, G-CSF - Granulocyte Colony-Stimulating Factor | Early Phase 1 | Unknown | Zhongnan Hospital | 40 | 2024-02-01 | 2024-01-18 |
| the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma PEG-rhG-CSF, RhG-CSF - Lymphoma | Not applicable | Unknown | Ou Bai, MD/PHD | 144 | 2023-05-01 | 2023-04-28 |
| Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies Etoposide, Cytarabine, PEG-rhG-CSF - Lymphoma, Multiple Myeloma | Not applicable | Unknown | The Affiliated People's Hospital of Ningbo University | 68 | 2022-11-01 | 2024-03-19 |
| Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies Etoposide, Cytarabine, PEG-rhG-CSF - Hematological Malignancy | Not applicable | Unknown | The Affiliated People's Hospital of Ningbo University | 62 | 2022-09-01 | 2023-10-10 |
Showing 20 of 80. Sign in to see all of them.
Lymphoma (10) · Breast Neoplasms (8) · Neutropenia (8) · Leukemia, Myeloid, Acute (7) · Multiple Myeloma (5) · Febrile Neutropenia (4) · Hematologic Neoplasms (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Monocytic, Acute (3) · Uterine Cervical Neoplasms (3) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2)
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (10) · National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (5) · Peking University (4) · The Affiliated People's Hospital of Ningbo University (4) · University of Washington (4) · City of Hope Medical Center (3) · Chinese Academy of Medical Sciences (2) · Chongqing University Cancer Hospital (2) · Emory University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Sun Yat-sen University (2) · Xiamen Amoytop Biotech Co., Ltd. (2) · Adello Biologics, LLC (1)
China (43) · United States (26) · Canada (4) · Australia (2) · Puerto Rico (2) · France (1) · Germany (1) · Netherlands (1) · New Zealand (1) · Sweden (1)
Ying Lu (3) · Alex F Herrera (2) · Roland Walter (2) · Antoinette J Wozniak (1) · Christina Poh (1) · David Shulman, MD (1) · Dongling Zou, M.D. (1) · Douglas W Sborov (1) · Filippo Milano, MD, PhD (1) · Fuling Zhou (1) · Guanghai Dai (1) · Huiqiang Huang (1) · Huiqiang Huang, professor (1) · Ida C Wong-Sefidan (1) · Jean H Hoffman-Censits (1)
PMID 21233311, PMID 31401903, PMID 32928136, PMID 34078317, PMID 34240339, PMID 37505794, PMID 38497347, PMID 38945791, PMID 39413375, PMID 40098083, PMID 40535475, PMID 40563015, PMID 41510127, PMID 41512237, PMID 42526889, PMID 42577949
P30CA033572 (3), U10CA180886 (2), U10CA180888 (2), P01CA078902 (1), P30CA015704 (1), P30CA138292 (1), P50CA107399 (1), R21DK078863 (1), U10CA032102 (1), U10CA180820 (1), U10CA180821 (1), UM1CA121947 (1)